NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/30/2024
Back to search
Official data from USPTO
AIM IMMUNOTECH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
07/30/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
09/04/2019
Registration date
07/30/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/30/2024
Last transaction
07/30/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/07/2023
First use in commerce
06/07/2023
Drawing code
3
Owner type
03
Owner location
Ocala, FL, US
Examiner
EULIN, INGRID
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a design of two curves with four horizontal lines between them, with the words "AIM ImmunoTech" to the right of the design and the word "AIM" above the word "ImmunoTech".
Holders and representatives
Holders
AIM ImmunoTech Inc.
Representatives
DONNA J. BUNTON NIXON & VANDERHYE P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Intravenous solution for use in the treatment of viral infectionsimmune disorderscancer and ME/CFS; intravenous solution for use in the treatment of viral infectionsimmune disorderscancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgerythermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseasesimmunological disorders and cancer; Pharmaceutical productspharmaceutical preparations for treatment of viral and infectious diseasescancerimmune disorders and ME/CFS; intranasal solutions for use as a vaccine adjuvantall of the foregoing primarily available by prescription
Class 42
Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancersviral diseasesimmunological disorders and ME/CFS
Publications
History of USPTO decisions and trademark events.
44 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/30/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/21/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/21/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/18/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/18/2024
ALIE
ASSIGNED TO LIE
06/18/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/09/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
11/09/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
11/09/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/09/2023
GNRT
NON-FINAL ACTION E-MAILED
08/09/2023
CNRT
SU - NON-FINAL ACTION - WRITTEN
08/09/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/19/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/19/2023
IUAF
USE AMENDMENT FILED
06/23/2023
EISU
TEAS STATEMENT OF USE RECEIVED
06/23/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/04/2023
EX3G
SOU EXTENSION 3 GRANTED
05/02/2023
EXT3
SOU EXTENSION 3 FILED
05/02/2023
EEXT
SOU TEAS EXTENSION RECEIVED
05/02/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/04/2022
EX2G
SOU EXTENSION 2 GRANTED
11/02/2022
EXT2
SOU EXTENSION 2 FILED
11/02/2022
EEXT
SOU TEAS EXTENSION RECEIVED
11/02/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/04/2022
EX1G
SOU EXTENSION 1 GRANTED
05/02/2022
EXT1
SOU EXTENSION 1 FILED
05/02/2022
EEXT
SOU TEAS EXTENSION RECEIVED
05/02/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/02/2021
TMBN
TTAB RELEASE CASE TO TRADEMARKS
09/22/2021
OP.T
OPPOSITION TERMINATED NO. 999999
09/22/2021
OP.D
OPPOSITION DISMISSED NO. 999999
09/22/2021
DOCK
ASSIGNED TO EXAMINER
07/23/2020
OP.I
OPPOSITION INSTITUTED NO. 999999
07/06/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
01/09/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/07/2020
PUBO
PUBLISHED FOR OPPOSITION
01/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/18/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/03/2019
DOCK
ASSIGNED TO EXAMINER
11/22/2019
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/17/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/16/2019
NWAP
NEW APPLICATION ENTERED
09/07/2019
Continuous trademark protection
Get notified about every new filing that threatens AIM IMMUNOTECH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.